Results 41 to 50 of about 22,597,991 (289)
Journal of Blood Medicine, 2022 Randall Curtis,1 Marilyn Manco-Johnson,2 Barbara A Konkle,3 Roshni Kulkarni,4 Joanne Wu,5 Judith R Baker,6 Megan Ullman,7 Duc Quang Tran Jr,8 Michael B Nichol5 1Factor VIII Computing, Berkeley, CA, USA; 2Hemophilia and Thrombosis Center, University of ...
Curtis R +8 more
doaj
Blood, 2020 Factor VIII (FVIII) replacement products enable comprehensive care in hemophilia A. Treatment goals in severe hemophilia A are expanding beyond low annualized bleed rates to include long-term outcomes associated with high sustained FVIII levels.
Ekta Seth Chhabra +29 more
semanticscholar +1 more source
Veterinary Sciences, 2022 A ten-week-old male Golden retriever puppy was presented with severe hyperesthesia, mild neurological deficits and episcleral bleeding. Clotting times showed a normal prothrombin time (PT) and prolonged activated partial thromboplastin time (aPPT ...
Charlotte Lubbers +3 more
doaj +1 more source
Emicizumab for the treatment of acquired hemophilia A.
Blood, 2020 Acquired hemophilia A (AHA) is a severe bleeding disorder caused by inhibiting autoantibodies to coagulation factor VIII (FVIII). For hemostatic treatment, bypassing agents, human or porcine FVIII are currently standard of care.
P. Knoebl +5 more
semanticscholar +1 more source
Randomized trial of a DVD intervention to improve readiness to self-manage joint pain [PDF]
, 2011 Report of a randomized controlled trial of a motivational intervention to promote self-management of joint painA DVD (digital video disk) intervention to increase readiness to self-manage joint pain secondary to hemophilia was informed by a 2-phase ...
Abraham +43 more
core +2 more sources
Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques [PDF]
, 2002 The feasibility, safety, and efficacy of liver-directed gene transfer was evaluated in 5 male macaques (aged 2.5 to 6.5 years) by using a recombinant adeno-associated viral (rAAV) vector (rAAV-2 CAGG-hFIX) that had previously mediated persistent ...
Davidoff, AM +12 more
core +1 more source
"Prevalence of inhibitors in a population of 1280 Hemophilia A patients in Iran " [PDF]
Acta Medica Iranica, 2003 Development of inhibitor to factor VIII is the most serious complication of hemophilia therapy. To determine the prevalence of inhibitors in Iran hemophilia A patients exposed to blood products, 1280 hemophilia A patients (age range 9 months-84 years ...
Sharifian R +6 more
doaj +2 more sources
Journal of Thrombosis and Haemostasis, 2010 Mild hemophilia A (HA), defined by clinical features and factor VIII coagulant activity (FVIII:C) between 0.05 and 0.40 IU mL(-1), is characteristically distinct from severe HA. Indeed, although the molecular characterization of mild HA has permitted the identification of specific underlying mutations, its clinical phenotype is strikingly different ...
Franchini M +2 more
openaire +3 more sources
Hemophilia management: Huge impact of a tiny difference
Research and Practice in Thrombosis and Haemostasis, 2020 Hemophilia A and B are inherited X‐linked disorders of hemostasis, associated with an increased bleeding tendency. Patients with severe hemophilia have undetectable clotting factor levels and experience spontaneous bleeds.
Fabienne Kloosterman +5 more
doaj +1 more source
Perfil clínico e epidemiológico de crianças e adolescentes com hemofilia em um centro de referência
Residência Pediátrica, 2023 OBJECTIVE: To identify clinical and epidemiological data of children and adolescents with hemophilia followed at the Center for Hematology and Hemotherapy of Piaui, characterizing them in terms of age, place of residence, type, severity, main ...
Marcela Bezerra Marques +1 more
doaj +1 more source